Jaguar Health JAGX shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and a $5 price target.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.
The company’s Mytesi is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
At the time of publication, shares of Jaguar Health were trading 8.3% higher at $1.61. The stock has a 52-week low of $0.185 and a 52-week high of $4.47.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.